论文部分内容阅读
目的:探究倍他乐克用于扩张型心肌病的价值探讨及药理。方法:选取60例扩张型心肌病患者按照治疗方法分为两组(各30例),观察组倍他乐克,对照组常规治疗。结果:观察组患者LVED(左室舒张末期内径)、HR(心率)和SBP(收缩压)均显著低于对照组和治疗前,但LVEF(左室射血分数)和MD(6 min内步行距离)显著高于对照组患者和治疗前,且再次入院率和猝死率均显著低于对照组患者(3.3%、3.3%和26.7%、23.3%),差异有显著性(P<0.05)。结论:倍他乐克可显著改善扩张型心肌病患者临床症状,降低患者再次入院率和猝死率。
Objective: To explore the value of Betaloc for dilated cardiomyopathy and its pharmacology. Methods: Sixty patients with dilated cardiomyopathy were divided into two groups (30 cases each) according to the method of treatment. The patients in the observation group received metoprolol and the control group received routine treatment. Results: The LVED, HR and SBP in the observation group were significantly lower than those in the control group and before treatment, but LVEF and MD (3.3%, 3.3%, 26.7%, 23.3%, respectively) were significantly higher than those in the control group (P <0.05). Conclusion: Betaloc can significantly improve the clinical symptoms of patients with dilated cardiomyopathy and reduce the rate of hospital admission and sudden death.